Harbour BioMed to develop and commercialise HanAll ’s biologic therapies in Greater China

South Korean pharmaceutical company HanAll Biopharma has entered a strategic collaboration and licence agreement with China-based Harbour BioMed for the development, production and commercialisation of two new biologic therapies in Greater China, inc …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news